LXEO
NASDAQ · Biotechnology
Lexeo Therapeutics Inc
$5.83
+0.01 (+0.17%)
Open$5.82
Previous Close$5.82
Day High$5.96
Day Low$5.67
52W High$10.99
52W Low$2.43
Volume—
Avg Volume522.9K
Market Cap431.19M
P/E Ratio—
EPS$-2.19
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+697.1% upside
Current
$5.83
$5.83
Target
$46.47
$46.47
$27.16
$46.47 avg
$57.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |
| Rev Growth | +16.0% | -2.8% | +7.5% |
| Debt/Equity | 0.49 | 0.46 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |